UK researchers have reported early signs that an immune targeted medicine already used in rheumatology could help some people with depression who do not improve on standard treatment. A University of Bristol team tested tocilizumab, a drug that blocks interleukin 6 signalling in the immune system, and found potential benefit in patients with difficult to treat depression. The findings point to a possible role for anti inflammatory therapy in mental health care, a field that has long relied on antidepressants and talking therapies that do not work for everyone. Clinicians and regulators stressed that this remains an early clinical signal rather than a new treatment ready for routine care. Further studies will need to show who benefits, how durable any effect is, and how to manage safety.
The team carried out the work in the UK and reported the results on 20 May 2026. The University of Bristol led the early clinical trial. The university has not announced any change to treatment advice, and national guidance remains unchanged.
What the early trial tested
The Bristol researchers explored whether repurposing tocilizumab, widely used in rheumatoid arthritis and other immune conditions, could reduce symptoms in people with depression who had not improved after conventional antidepressants. The study set out to test if targeting inflammation, rather than brain chemistry alone, can make a measurable difference for patients whose options have narrowed. The researchers observed promising improvements in depressive symptoms in this group.
Tocilizumab works by blocking the receptor for interleukin 6, a key messenger in the immune response. Doctors already use it to treat inflammatory joint disease and other immune mediated disorders in the NHS. The trial did not change national treatment guidance. It provides an early signal that warrants larger, carefully controlled studies to confirm benefit, identify who gains most, and monitor safety over time.
Why inflammation matters in some depression
A growing body of research suggests that inflammation and the immune system play a role in depression for a subset of patients. Studies have linked higher levels of inflammatory markers, including interleukin 6, with more severe symptoms and reduced response to standard antidepressants. This line of work has encouraged teams to test immunomodulating drugs in carefully selected patients who show signs of ongoing inflammation.
The Bristol findings add weight to the idea that tailoring treatment to biology could help people who have not responded to other options. Not all depression involves inflammation, and the majority of patients will not need immune based therapy. The current result does not change that. It suggests a path to test whether people with clear inflammatory features might benefit from treatments that act on the immune system, alongside established mental health care.
What this means for patients and clinicians now
Care remains the same for people with depression. Tocilizumab is not licensed for psychiatric use, and doctors should not switch patients to immune based therapy on the basis of one early study. The NHS must follow evidence based guidance. Any future use for depression would require clear proof from larger trials, regulatory review, and new clinical pathways to assess and monitor patients safely.
Tocilizumab can increase the risk of infections and requires regular blood tests and clinical oversight. The drug is delivered by injection or infusion and costs significantly more than standard antidepressants. These factors matter in any assessment of risk and benefit. For now, patients should continue current care plans and discuss any concerns with their GP or mental health team rather than seeking off label use.
Regulatory and service steps if evidence grows
Before any immune therapy could become a routine option in depression care, regulators would need to license the medicine for that purpose. In the UK, the Medicines and Healthcare products Regulatory Agency would assess the evidence on safety and effectiveness. The National Institute for Health and Care Excellence would then review the data and consider cost effectiveness for the NHS, including service capacity and monitoring needs.
Introducing a biologic therapy into mental health services would require new pathways. Teams would need to agree on criteria to identify patients most likely to benefit, probably using simple inflammatory markers. Services would need access to infusion or injection facilities, clear safety monitoring, and joint working between psychiatry, rheumatology, and primary care. Commissioners would need to plan for workforce time and costs if future guidance supports use.
How this fits within the research landscape
Trials of anti inflammatory approaches for depression have shown mixed results to date. Some studies of non steroidal anti inflammatory drugs and cytokine blockers have reported benefit in subgroups, while others have not. The field now focuses on better patient selection, consistent outcome measures, and longer follow up. The Bristol study adds a signal for interleukin 6 blockade that will need replication in larger groups and across different settings.
Future research will likely test stratified recruitment, where patients with raised inflammatory markers join studies of immune targeted drugs, while others follow different protocols. Trials will also examine how these therapies combine with antidepressants, psychological therapies, and lifestyle based support already used in care plans. Safety remains central. Researchers will track infection rates and other known risks that come with immune modulation.
Practical implications for the NHS and communities
If further studies confirm benefit for a defined group, health services would need to weigh up the clinical gains against practical and financial demands. Biologic drugs often require regular appointments and blood tests. That can add pressure to hospital day units and community services already managing high demand. Clear referral routes and shared care agreements would be essential to avoid delays and confusion for patients.
Public communication would also matter. Immunotherapy in cancer differs from immune modulating drugs in inflammatory disease, but people often hear the same term used for both. Health bodies would need to explain what the treatment does, who it is for, and what to expect. Keeping messages simple and accurate would help avoid false hope or inappropriate requests for a medicine that remains unlicensed for depression.
What patients and families should watch for next
Over the coming months, look for announcements of larger trials that test tocilizumab in more patients with hard to treat depression. These studies should set out how they select participants, how they measure change in symptoms and function, and how long they follow people. Independent replication will matter as much as the size of the effect. Any talk of routine use will depend on consistent results across more than one study.
Patients and families should expect guidance to reflect the evidence as it develops. If further trials confirm benefit in a clear subgroup, professional bodies and national agencies would issue advice on testing, referral, and monitoring. Until then, the NHS will maintain current pathways for depression and focus on improving access to timely assessment, psychological therapies, and medicine review.
The Bristol team has opened a path that could change care for a defined group of patients, but it remains early. An established immune drug appears to reduce depression symptoms in people who did not respond to antidepressants, at least in a small trial setting. That offers cautious optimism while underlining the need for larger, longer studies. For now, treatment stays the same, safety standards remain high, and regulators will expect strong, consistent data before they consider any new licence or guidance. If the signal holds in bigger trials, the NHS will face practical questions on patient selection, delivery, and cost but also the chance to add a targeted option for those most in need.
